Article Versions Notes

Poggialini F, Vagaggini C, Brai A, Pasqualini C, Crespan E, Maga G, Perini C, Cabella N, Botta L, Musumeci F, et al. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics. 2023; 15(2):453. https://doi.org/10.3390/pharmaceutics15020453

Poggialini, Federica, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Emmanuele Crespan, Giovanni Maga, Cecilia Perini, Noemi Cabella, Lorenzo Botta, Francesca Musumeci, and et al. 2023. "Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme" Pharmaceutics 15, no. 2: 453. https://doi.org/10.3390/pharmaceutics15020453

Poggialini, F., Vagaggini, C., Brai, A., Pasqualini, C., Crespan, E., Maga, G., Perini, C., Cabella, N., Botta, L., Musumeci, F., Frosini, M., Schenone, S., & Dreassi, E. (2023). Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics, 15(2), 453. https://doi.org/10.3390/pharmaceutics15020453